地夫可特对杜氏肌营养不良症青春期的影响。
The impact of deflazacort on puberty in Duchenne muscular dystrophy.
机构信息
Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
出版信息
Pediatr Neurol. 2013 Oct;49(4):292-3. doi: 10.1016/j.pediatrneurol.2013.05.004. Epub 2013 Aug 3.
BACKGROUND
The routine use of glucocorticoids has increased the longevity of patients with Duchenne muscular dystrophy. Long-term steroid therapy may have adverse effects on endocrine function and could influence the onset of puberty.
METHODS
We assessed the pubertal development of our patients who were 14 years of age or older and had been treated with deflazacort as their only glucocorticoid.
RESULTS
Half (6 of 12) of the boys who were treated with deflazacort had pubertal delay. There was no difference in the age of onset, dose, or duration of deflazacort therapy between those who did and did not have delayed puberty.
CONCLUSIONS
This pilot study suggests that delayed puberty should be studied in future trials that address different doses and schedules of deflazacort therapy in Duchenne muscular dystrophy.
背景
常规使用糖皮质激素延长了杜氏肌营养不良症患者的寿命。长期类固醇治疗可能对内分泌功能有不良影响，并可能影响青春期的开始。
方法
我们评估了 14 岁及以上且仅接受地夫可特作为糖皮质激素治疗的患者的青春期发育情况。
结果
接受地夫可特治疗的 12 名男孩中有一半（6 名）出现青春期延迟。青春期延迟和无延迟的患者在开始年龄、地夫可特剂量或治疗持续时间方面无差异。
结论
这项初步研究表明，未来应在不同剂量和地夫可特治疗方案的临床试验中研究青春期延迟的问题。
Zotero 插件